Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolinapant + Eribulin in Metastatic TNBC
NCT06590558Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tolinapant in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events, Dose-limiting toxicities up to 4 weeks and 1 more. Planned start Aug 2025; status: withdrawn.
02
Drugs
tolinapant
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06590558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590558.